# Vijay Lathi

> Vijay Lathi is a Series C investor at New Leaf Venture Partners backing Health Care and Medical. See 26 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners)
- Location: San Mateo, United States
- Total investments: 26
- Last investment: Jan 2026
- Lead investor: 23%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/vijay-lathi-3011b61/

Vijay Lathi is a Series C investor at New Leaf Venture Partners in San Mateo focused on Health Care and Medical. Vijay Lathi - Managing Director @ New Leaf Venture Partners

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 42% |
| Medical | 7 | 27% |
| Software | 5 | 19% |
| Biotechnology | 4 | 15% |
| Information Technology | 4 | 15% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 8 | 31% |
| Series B | 7 | 27% |
| Series A | 3 | 12% |
| Series D | 2 | 8% |
| Venture - Series Unknown | 2 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 46% |
| Canada | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BrightInsight | BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was foundedin 2017 and is headquartered in San Jose, California. | $13M | Venture - Series Unknown | Jan 20, 2026 |  |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M | Series C | Oct 22, 2025 |  |
| Star Therapeutics | Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $125M | Series D | Sep 30, 2025 |  |
| Truveris | Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market accesschallenges.Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital. | $15M | Series E | May 14, 2024 |  |
| Flosonics | Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. | $20M | Series C | Mar 19, 2024 |  |
| Star Therapeutics | Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $90M | Series C | Sep 05, 2023 |  |
| Cleerly | Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway.Throughthese data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks. | $223M | Series C | Jul 25, 2022 |  |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $84M | Series B | Feb 16, 2022 |  |
| Star Therapeutics | Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients. | $100M | Venture - Series Unknown | Feb 16, 2022 |  |
| Cleerly | Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway.Throughthese data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks. | $43M | Series B | Jun 21, 2021 |  |

10 of 26 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 7 deals together
- [Westlake Village BioPartners](https://shizune.co/investors/profile/westlake-village-biopartners) — VC Fund, 6 deals together
- [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 5 deals together
- [Eclipse](https://shizune.co/investors/profile/eclipse-ventures) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 5 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 5 deals together

## About New Leaf Venture Partners

VC Fund · New York, United States

New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, theventure capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

5 contacts available at New Leaf Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Craig Slutzkin | CFO & COO | https://shizune.co/investors/profile/craig-slutzkin |
| James Niedel | Managing Director | https://shizune.co/investors/profile/james-niedel |
| Liam Ratcliffe | Managing Director | https://shizune.co/investors/profile/liam-ratcliffe |
| Ronald Hunt | Managing Director | https://shizune.co/investors/profile/ron-hunt-2 |
| Vijay Lathi | Managing Director | https://shizune.co/investors/profile/vijay-lathi |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Vijay Lathi invest in?

Vijay Lathi invests primarily in Health Care, Medical and Software startups, most often at Series C and Series B stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Vijay Lathi last invest?

The most recent investment recorded for Vijay Lathi closed in Jan 2026. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co